Search results
Results from the WOW.Com Content Network
Prasugrel, sold under the brand names Effient and Efient, is a medication used to prevent formation of blood clots.It is a platelet inhibitor and an irreversible antagonist of P2Y 12 ADP receptors and is of the thienopyridine drug class.
Credit - Getty Images. T oo many seniors are prescribed too many drugs. About four of every 10 older adults take five or more medications, triple the rate from two decades ago. Almost 11 million ...
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses.
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales. Abbreviations are used in the list as follows: INN = International Nonproprietary Name
While semaglutide is an injectable medication that is FDA-approved for type 2 diabetes with the name brand Ozempic, it has also been FDA-approved for weight loss under the brand name Wegovy.
Still used as veterinary drug and as a human antihelminthic in many markets; listed on the WHO List of Essential Medicines. In humans, it was used to treat melanoma before it was withdrawn for agranulocytosis. [29] [30] [31] Levomethadyl acetate: 2003 US Cardiac arrhythmias and cardiac arrest. [2] Lorcaserin (Belviq) 2020 US Increased risk of ...
The study analyzed records of more than 125,000 adults who began taking the GLP-1 drugs liraglutide, semaglutide, or tirzepatide between January 2018 and December 2023.